Sign in

Research summary ·

[Impact of TERT and CDKN2A/B driver mutations on meningioma recurrence: a systematic review and meta-analysis].

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This review pooled results from earlier studies on meningioma, a type of tumor. The team looked at changes in the TERT gene and the CDKN2A/B genes. They asked if these changes were linked to the tumor coming back. They combined 17 studies with 5867 people in total. They looked at how long people lived and how long before tumors grew again. They also split the results by tumor grade, from Grade 1 to Grade 3.

What they found

People whose tumors had a TERT change had a worse outlook. They had a higher risk of death and of tumor growth. The TERT effect was strong in Grade 1 and 2 tumors. It was weaker in Grade 3 tumors. Loss of both copies of CDKN2A/B was linked to the tumor coming back early. This held across all tumor grades. Changes found with Sanger sequencing told more than those found with NGS.

What it means for patients

The authors conclude TERT testing is key for Grade 1 and 2 meningiomas. This may help spot tumors that are more aggressive than they seem. For Grade 3 tumors, they see CDKN2A/B testing as the main priority. Such gene tests may help doctors judge the risk of the tumor coming back.

Why it is not certain yet

This review combined studies that followed groups of people. A review can only be as good as the studies in it. The abstract does not describe the quality of the included studies. Results also depended on which type of gene test was used. The abstract does not say how long people were followed.

Source

[Impact of TERT and CDKN2A/B driver mutations on meningioma recurrence: a systematic review and meta-analysis].

PubMed · PMID 42885131

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Meningioma publications